Novartis eyes office expansion in Dublin; Indian pharma gets big thumbs up from HSBC;

Newspapers

 @FiercePharma: Thumbs up from HSBC on India's pharma sector. Dr Reddy's, Sun Pharma, Cipla are its faves--Reuters. More | Follow @FiercePharma

> Novartis ($NVS) is reportedly scouting for more office space in Dublin, with plans to lease 100,000 square feet of additional space, sources tell Bloomberg. Report

> Transcept Pharmaceuticals and its marketing partner Purdue Pharma will benefit long-term from a newly issued method-of-use patent on the sleep drug Intermezzo, analysts said. 

> HSBC analysts hiked price targets on several Indian drugmakers, saying U.S. drug launches and "robust" earnings support premium valuations for the likes of Dr. Reddy's Labs, Sun Pharma and Cipla, among others. Report

> Glenmark Pharmaceuticals prevailed in arbitration with a former partner, winning the right to sell Crofelemer, its drug for HIV-associated diarrhea, in 140 countries. Report

> New policies from the Venezuelan government may inhibit foreign drugmakers' ability to import finished drugs and bulk ingredients. Report

> SkyePharma's asthma drug Flutiform won approval from U.K. regulators; the company expects to launch this year. Report

Medical Device News

@FierceMedDev: The FBI arrested two former ArthoCare execs, charging them with defrauding investors of $400M. Release | Follow @FierceMedDev

 @MarkHFierce: Faridabad in India is becoming a huge hub for medical device and equipment manufacturers. More | Follow @MarkHFierce

 @DamianFierce: CareFusion's fourth Class I recall of the summer deals with is Alaris infusion pumps. Article | Follow @DamianFierce

> Varian Medical chooses South Korea for overseas subsidiary. News

> Devicemakers cautiously optimistic after meeting with FDA chief. Story

> GI Dynamics gains FDA nod for obesity device pivotal trial. Item

> CareFusion hit with another Class I recall over pump. News

Biotech News

 @FierceBiotech: From FierceCRO: Researchers bristle at India's proposed trial reforms. Story | Follow @FierceBiotech

 @JohnCFierce: Fate Therapeutics raised a bit more than $9M for their stem cell work. Run by biotech vet Bill Rastetter. More | Follow @JohnCFierce

 @RyanMFierce: J&J is heading into Phase III with a new RA drug, add on big inflammation biz, not sure what hopes are for this one. More | Follow @RyanMFierce

> Stem cell biotech Fate nails down $9.2M. News

> ImmunoGen rises on hopes for encores to Roche's armed breast cancer drug. Story

> PRA sets up China shop with interest in Asia growing. More

Vaccines News

> Bavarian Nordic in peril if U.S. nixes smallpox vaccine order. Report

> Labs, NIH zero in on painless vaccine technology. More

> NIAID provides $7.8M in grants for HIV research. Article

> PATH Malaria Vaccine Initiative creates reference lab. Item

> Merck's Varivax slashes U.S. chickenpox cases. Story

Pharma Manufacturing News

> EU inspectors give Alexza plant the approval that FDA denied it. News

> West tapping growth in India, Asia. More

> Forfeiture of 27 ANDAs is a small piece of Ranbaxy penalties. Item

And Finally... National Institutes of Health researchers proved super-sleuths in a hospital outbreak, using gene sequencing to snuff out the spread of infection. Report